All Updates

All Updates

icon
Filter
Partnerships
SkylineDx partners with NeraCare to co-develop Immunoprint
Precision Medicine
Apr 20, 2023
This week:
Product updates
Burcon unveils canola protein isolate for egg replacement
Plant-based Dairy & Egg
Yesterday
Product updates
Bene Meat Technologies produces first cultivated burger at parity with premium beef
Cell-cultured Meat
Yesterday
Geographic expansion
Regulation/policy
The Better Meat Co. expands to Asia with Singapore approval for Rhiza mycoprotein
Plant-based Meat
Yesterday
Listing
Pony.ai files for US IPO
Auto Tech
Yesterday
Product updates
MineOS launches DSR management 2.0
Digital Privacy Tools
Yesterday
Product updates
LatticeFlow launches the first evaluation framework for EU AI Act compliance
Generative AI Infrastructure
Yesterday
Product updates
Cognitive3D launches custom dashboards for XR analytics
Extended Reality
Oct 16, 2024
Funding
Mindtech raises GBP 4.4 million in funding to develop AI vision technology
Extended Reality
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Identity & Access Management
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Next-gen Cybersecurity
Oct 16, 2024
Precision Medicine

Precision Medicine

Apr 20, 2023

SkylineDx partners with NeraCare to co-develop Immunoprint

Partnerships

  • Netherlands-based molecular diagnostic company SkylineDx has entered a strategic partnership with German lab developer NeraCare to co-develop a proteomic test called “Immunoprint” for survival prediction of melanoma patients.

  • Immunoprint by NeraCare will help life science companies bring melanoma therapies to market faster by identifying high-risk, early-stage melanoma patients. Both companies will work exclusively together to develop and license Immunoprint while leveraging SkylineDx's global network and discovery expertise, and will present validation data at the 2023 European Association of Dermato-Oncology congress.

  • SkylineDx is a biotech company specializing in molecular diagnostics for oncology and inflammatory diseases. SkylineDx's lead product is MMprofiler with SKY92, a clinical test that measures the activity of 92 cancer genes and is used to aid physicians in the prognosis of multiple myeloma. The company also has a R&D program called “Falcon” that aims to develop an array of diagnostic utilities for melanoma patients, providing physicians with the tools to optimize the clinical pathway of their patients. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.